TherapeuticsMD, Inc. (TXMD)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $1.79
- As of
Kresmion compiles this page from TXMD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TherapeuticsMD, Inc. (TXMD): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
See the full TXMD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TXMD on one page. Preview it with sample data, then open it live with a free account.
Preview the TXMD dossierActive events for TXMD
- high13F: large increase
CITADEL ADVISORS LLC added +205% to TXMD (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +52% to TXMD (2026Q1)
- mediumEarnings below estimates
Q3-2023: Missed consensus by 154.9% - EPS $-0.13 vs $-0.051 estimate
- mediumEarnings above estimates
Q4-2022: Beat consensus by 826.9% - EPS $8.23 vs $-1.1322 estimate
- mediumEarnings below estimates
Q1-2023: Missed consensus by 704.6% - EPS $-0.37 vs $0.0612 estimate
FREE, NO ACCOUNT
Every event on TXMD, as it fires
You are seeing 5 of 7 events recorded on TXMD since 2026-06-05.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TXMD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 88338N206 · 2026Q2 | $324K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 88338N206 · 2026Q2 | $190K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TXMD
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
TXMD against its peers
TXMD's operating margin of -145.3% ranks in the 12th percentile of 12 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | TXMD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.0M USD | 34.2M USD | 21 | 16 |
| Gross margin | n/a | 45.6% | n/a | 13 |
| Operating margin | -145.3% | -12.6% | 12 | 12 |
| Net margin | -18.8% | -22.7% | 57 | 14 |
| Return on equity | -2.1% | -26.6% | 90 | 14 |
Peers (18): AYTU, BIOE, MRMD, HYEX, SHPH, INIS, ITHUF, ETST, CPHI, RMTI, PLNH, RAPH, CXXIF, IXHL, BFRI, CABR, SCYX, UPC. Left out: ROMJF (no annual filing), OPTH (no annual filing), CPIVF (no annual filing), HSTI (period gap), MCUJF (period gap), TRUFF (no annual filing), CYPA (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TXMD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TXMD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TXMD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.